Mitochondrial “power” drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer

Here, we identified two new molecular targets, which are functionally sufficient to metabolically confer the tamoxifen-resistance phenotype in human breast cancer cells. Briefly, ~20 proteins were first selected as potential candidates, based on unbiased proteomics analysis, using tamoxifen-resistan...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiorillo, Marco, Sotgia, Federica, Sisci, Diego, Cappello, Anna Rita, Lisanti, Michael P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386764/
https://www.ncbi.nlm.nih.gov/pubmed/28411284
http://dx.doi.org/10.18632/oncotarget.15852

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386764/
https://www.ncbi.nlm.nih.gov/pubmed/28411284
http://dx.doi.org/10.18632/oncotarget.15852

Ejemplares similares